Silence Therapeutics PLC
Company Profile
Business description
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
Contact
72 Hammersmith Road
LondonW14 8TH
GBRT: +44 2034576900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
116
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,841.90 | 8.30 | 0.09% |
CAC 40 | 7,696.27 | 58.28 | -0.75% |
DAX 40 | 23,787.45 | 146.68 | -0.61% |
Dow JONES (US) | 44,828.53 | 344.11 | 0.77% |
FTSE 100 | 8,822.91 | 0.29 | -0.00% |
HKSE | 23,916.06 | 153.88 | -0.64% |
NASDAQ | 20,601.10 | 207.97 | 1.02% |
Nikkei 225 | 39,810.88 | 24.98 | 0.06% |
NZX 50 Index | 12,766.60 | 62.12 | 0.49% |
S&P 500 | 6,279.35 | 51.93 | 0.83% |
S&P/ASX 200 | 8,603.00 | 7.20 | 0.08% |
SSE Composite Index | 3,472.32 | 11.17 | 0.32% |